FDA Gives Green Light for Multiple Sclerosis Stem Cell Trial

Non-profit research organization Hope Biosciences Stem Cell Research Foundation has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis.